[Treatment of acute and recurrent vulvovaginal candidiasis (VVC/rVVC)--state of art in 2008. Expert Board of Polish Gynecological Society].
Vulvovaginal infection is the most common cause of gynecological problems in sexually active women. Few years ago it was not considered as serious disease which may cause major health implications. Currently we are aware that it implies life worsening, temporal indisposition, postoperative complications and even life threatening sepsis in patients hospitalized in Intensive Care Units. Knowledge about pharmacological properties of drugs used in treatment vulvovaginal candidiasis allows for tailoring therapy to each patient. Fluconazole is modern and up to date option for treatment of VVC/rVVC. Short- and long-term therapeutic efficacy of fluconazole was confirmed in numerous high reliability clinical trials. Good tolerance, wide range of single therapeutic dose and high level of patient's acceptance gives the specialist powerful and efficient tool for management of VVC/rVVC.
Kotarski
Jan
J
Drews
Krzysztof
K
Maleszka
Romuald
R
Rechberger
Tomasz
T
Woroń
Jarosław
J
Tomaszewski
Jacek
J
D000208:Acute Disease; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D002908:Chronic Disease; D003226:Congresses as Topic; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007318:Inservice Training / Q000592:standards; D009313:National Health Programs / Q000592:standards; D011044:Poland; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D011785:Quality Assurance, Health Care / Q000592:standards; D012008:Recurrence; D012955:Societies, Medical / Q000592:standards; D016387:Women's Health
D000935:Antifungal Agents